KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) Other Non Operating Income (2016 - 2026)

Edwards Lifesciences has reported Other Non Operating Income over the past 11 years, most recently at $3.2 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 90.39% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $7.2 million, down 89.55%, while the annual FY2025 figure was $7.2 million, 89.55% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $3.2 million at Edwards Lifesciences, up from $2.7 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $33.3 million in Q4 2024 and troughed at -$3.3 million in Q1 2022.
  • A 5-year average of $5.4 million and a median of $2.9 million in 2025 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 1566.67% in 2021 and later tumbled 242.86% in 2022.
  • Year by year, Other Non Operating Income stood at $1.4 million in 2021, then skyrocketed by 314.29% to $5.8 million in 2022, then plummeted by 37.93% to $3.6 million in 2023, then soared by 825.0% to $33.3 million in 2024, then plummeted by 90.39% to $3.2 million in 2025.
  • Business Quant data shows Other Non Operating Income for EW at $3.2 million in Q4 2025, $2.7 million in Q3 2025, and -$1.3 million in Q2 2025.